drugset / Trial / NCT07613450
A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, controlled, open-label, multicenter, Phase III clinical study designed to compare the efficacy and safety of SYHA1813 versus treatment of investigators' choice in patients with recurrent or progressive high-grade meningioma not amenable to local therapy.
Timeline
- Start
- 2026-05-20
- Primary completion
- 2029-07-31
- Completion
- 2029-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Hydroxyurea | Other / unclassified | — | — |
| Subject | SYHA1813 | Unknown | 20 mg | — |
| Subject | Temozolomide | Small molecule | — | — |